Search 

Fluence Therapeutics is commercializing photodynamic therapy for the treatment of psoriasis and other skin diseases.

We have successfully completed Phase Ia studies and are seeking funding for the completion of a Phase Ib/IIa proof of concept study in Tampere, Finland.

Current therapies are not adequate for the treatment of difficult cases of psoriasis.  Current light therapies use UV light, which is a known carcinogen, requires many treatments and results in premature photoaging.  Systemic pharmaceuticals globally suppress the immune system, resulting in increased rates of infection and certain kinds of cancers. 

Our therapy uses a novel photosensitizer which is activated by harmless red light and, unlike ALA PDT, does not result in pain or residual photosensitivity.  It can treat multiple, large lesions simultaneously.  It is totally inert unless activated by visible red light.  When activated, it preferentially kills activated t cells over other skin cells.